Back to search

Peptide record

TPDB10841

Antibacterial Anticancer Hemolysis Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10841
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GRFKRFRKKFKKLFKKLSPVIPLLHL
Physicochemical Analysis
C158H262N44O28
ANDCEQMTWY
K
3226.10
12.73
11
0
11
+10
3.80
-0.365
101.15
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
0
A
3
R
0
N
0
D
0
C
0
E
0
Q
1
G
1
H
1
I
5
L
7
K
0
M
4
F
2
P
1
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 1 I: 1 L: 5 K: 7 M: 0 F: 4 P: 2 S: 1 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
26
C158H262N44O28
3226.10
12.73
+10
3.80
-0.365
Evidence Records 4 records
Evidence 1 Activity

Activity

22% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
22% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of nontoxic analogues of cathelicidin-derived bovine antimicrobial peptide BMAP-27: the role of leucine as well as phenylalanine zipper sequences in determining its toxicity. | Biochemistry | 2009
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
75 µM
Hemolytic Cytotoxic
50% Hemolysis | 75 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural analysis and mode of action of BMAP-27, a cathelicidin-derived antimicrobial peptide. | Peptides | 2019
Evidence 3 Activity

Activity

% Hemolysis
Toxicity
50 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.31226350] 50% hemolysis at 75 µM for human red blood cells | Cytotoxicity: [Ref.31226350] The CC50 values which represent peptide concentration (µM) inducing 50% cytotoxicity to human cancer cell lines of BMAP-27 on MDA361 and A549 are 4.2 µM and 5.3 µM. DETAILED DATA: ①The cell viability of MDA-361 induced by BMAP-27 is 100%, 100%, 98.9%, 97.7%, 87.6%, 59.8%, 34.7%, 12.4%, 10.3%, 8.3% and 9.4% at peptide concentrations of 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 13, 25, 50 and 100 µM. ②The cell viability of A549 induced by BMAP-27 is 100%, 99.1%, 97.7%, 94.7%, 74.5%, 41.4%, 24.4%, 11.3%, 9.7%, 10.3% and 7.4% at peptide concentrations of 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 13, 25, 50 and 100 µM.

Target

erythrocytes

Source & Reference

NA
DRAMP
Peptides. 2019 Jun 18 118:170106. doi: 10.1016/j.peptides.2019.170106.
Evidence 4 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis